Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer

Pellerino, 2020, Management of Brain and Leptomeningeal Metastases from Breast Cancer, Int J Mol Sci, 21, 8534, 10.3390/ijms21228534 Lin, 2008, Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases, Cancer, 113, 2638, 10.1002/cncr.23930 Murthy, 2020, Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer, N Engl J Med, 382, 597, 10.1056/NEJMoa1914609 Eguren-Santamaria I, Sanmamed MF, Goldberg SB, et al. PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice. 2020;26(16):4186-4197. Daly MB, Pilarski R, Yurgelun MB, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. 2020;18(4):380. Beaubier N, Tell R, Lau D, et al. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. 2019;10(24):2384. Beaubier N, Bontrager M, Huether R, et al. Integrated genomic profiling expands clinical options for patients with cancer. 2019;37(11):1351-60. Ma, 2016, Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy, J Hematol Oncol, 9, 47, 10.1186/s13045-016-0277-y Chen, 2020, Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors, Cancer Treat Res, 180, 251, 10.1007/978-3-030-38862-1_9 Goodman, 2018, Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors, JAMA Oncol, 4, 1237, 10.1001/jamaoncol.2018.1701 Curtis, 2012, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, 486, 346, 10.1038/nature10983 Pereira, 2016, The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes, Nat Commun, 7, 11479, 10.1038/ncomms11479 Gupta, 2019, Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management, J Mol Diagn, 21, 307, 10.1016/j.jmoldx.2018.10.006 Roesler, 2020, Abstract 1790: PDJ amplicon heterogeneity in triple negative breast cancers, Cancer Res, 80, 1790, 10.1158/1538-7445.AM2020-1790 Barrett, 2015, Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer, Oncotarget, 6, 26483, 10.18632/oncotarget.4494 Balko, 2016, Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence, Sci Transl Med, 8, 10.1126/scitranslmed.aad3001 Oechsle, 2010, Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis, J Cancer Res Clin Oncol, 136, 1729, 10.1007/s00432-010-0831-x Cohen, 2016, Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment, Cancer Immunol Res, 4, 179, 10.1158/2326-6066.CIR-15-0160 Kluger, 2019, Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial, J Clin Oncol, 37, 52, 10.1200/JCO.18.00204 Hendriks, 2019, Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors, J Thorac Oncol, 14, 1244, 10.1016/j.jtho.2019.02.009 Hubbeling, 2018, Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer, J Thorac Oncol, 13, 550, 10.1016/j.jtho.2018.01.012 Goldberg, 2020, Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial, Lancet Oncol, 21, 655, 10.1016/S1470-2045(20)30111-X Eguren-Santamaria, 2020, PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice, Clin Cancer Res, 26, 4186, 10.1158/1078-0432.CCR-20-0798 Nakashima, 2020, Whole-brain Radiation and Pembrolizumab Treatment for a Non-small-cell Lung Cancer Patient with Meningeal Carcinomatosis Lacking Driver Oncogenes Led to a Long-term Survival, Intern Med, 59, 1433, 10.2169/internalmedicine.4232-19 Schmid, 2018, Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer, N Engl J Med, 379, 2108, 10.1056/NEJMoa1809615 Schmid, 2020, Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 21, 44, 10.1016/S1470-2045(19)30689-8 Schmid, 2017, Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses, Cancer Res, 77, 2986, 10.1158/1538-7445.AM2017-2986 Duchnowska, 2016, Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis, Breast Cancer Res, 18, 43, 10.1186/s13058-016-0702-8 Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167(3):671-86. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460. Rugo HS, Delord JP, Im SA, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. Clin Cancer Res. 2018;24(12):2804-11. Tolaney, 2020, A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC)(ENHANCE 1), J Clin Oncol, 38, 1015, 10.1200/JCO.2020.38.15_suppl.1015 Adams, 2017, Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B, J Clin Oncol, 35, 1088, 10.1200/JCO.2017.35.15_suppl.1088 Cortés J, Lipatov O, Im SA, et al. KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann Oncol. 2019;30:v859-v60. Miles D, Gligorov J, André F, et al. LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC)±atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2020;31:S1147-S1148. Cortes, 2020, KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab+ chemotherapy versus placebo+ chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer, J Clin Oncol, 35, 1000, 10.1200/JCO.2020.38.15_suppl.1000 Cortes, 2020, Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial, Lancet, 396, 1817, 10.1016/S0140-6736(20)32531-9